XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma
Authors:
- 27 November 2010
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 29 (6) , 801-806
Abstract
Recent lung cancer data have shown an association of XPA-210, a key peptide of thymidine kinase, with advanced disease. We thus assessed its proliferation status in primary (M0) and metastatic (M1) renal cell carcinoma (RCC).Keywords
This publication has 25 references indexed in Scilit:
- Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settingsInternational Journal of Clinical Oncology, 2010
- Isolated gastric metastasis from renal cell carcinoma 19 years after radical nephrectomyInternational Journal of Clinical Oncology, 2010
- Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trialsAnnals of Oncology, 2010
- Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic markerEuropean Journal Of Cancer Prevention, 2009
- Renal Cell Carcinoma GuidelineEuropean Urology, 2007
- Clinical significance of serum neuron‐specific enolase in patients with adult T‐cell leukemiaAmerican Journal of Hematology, 2002
- p53, bcl-2 and Retinoblastoma Proteins as Long-Term Prognostic Markers in Localized Carcinoma of the ProstateJournal of Urology, 1997
- Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humansInternational Journal of Cancer, 1984
- Human mitochondrial thymidine kinase is coded for by a gene on chromosome 16 of the nucleusSomatic Cell and Molecular Genetics, 1977
- Assignment of the gene for galactokinase to human chromosome 17 and its regional localisation to band q21-22Nature, 1974